Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Midday stock movers: Alphabet, Super Micro, Eli Lilly and more

Midday stock movers: Alphabet, Super Micro, Eli Lilly and more

Here are the stocks making the biggest market moves.

Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs

Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs

Eli Lilly stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its diabetes and weight-loss drugs.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fact check: Weight loss drug trial, US election rules and ‘IDF soldiers’ image

Round up of fact checks from the last week compiled by Full Fact.

Evening Standard

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

Investors Business Daily

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

inkl

Read news from The Economist, FT, and more,
with one subscription

Donanemab – what we know about the latest Alzheimer’s drug

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

The Independent UK

Wes Streeting says weight-loss jabs for unemployed not 'dystopian'

Wes Streeting says weight-loss jabs for unemployed not 'dystopian'

THE UK’s Health Secretary has denied his plans to give weight-loss jabs to unemployed people would result in a “dystopian future”.

The National (Scotland)

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

The Guardian - UK

Experts weigh in on Labour plan to offer weight loss jabs to unemployed

Experts weigh in on Labour plan to offer weight loss jabs to unemployed

LABOUR plans to give obese and unemployed people weight-loss jabs as part of a drive to get them back into work and reduce pressure on the NHS…

The National (Scotland)

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The National (Scotland)

Unemployed to be given weight-loss jags as part of UK plan to 'get them back to work'

THE Health Secretary has said unemployed people will be given weight-loss injections as part of a UK Government drive to “get them back to…

Investors Business Daily

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Investors Business Daily

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

The list of 100 executives spans the globe.

Investors Business Daily

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

International Business Times

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the UK Government

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

231,327 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play